These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6433000)

  • 1. Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO].
    Martin GE; Williams M; Pettibone DJ; Yarbrough GG; Clineschmidt BV; Jones JH
    J Pharmacol Exp Ther; 1984 Sep; 230(3):569-76. PubMed ID: 6433000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity of (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] for dopamine receptors in vitro and in vivo.
    Martin GE; Williams M; Pettibone DJ; Zrada MM; Lotti VJ; Taylor DA; Jones JH
    J Pharmacol Exp Ther; 1985 May; 233(2):395-401. PubMed ID: 2987478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
    Koller W; Herbster G; Gordon J
    Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
    de Yebenes JG; Fahn S; Jackson-Lewis V; Mena MA
    Mov Disord; 1987; 2(4):291-9. PubMed ID: 2904650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.
    Meltzer LT; Caprathe BW; Christoffersen CL; Corbin AE; Jaen JC; Ninteman FW; Pugsley TA; Serpa KA; Shih YH; Whetzel SZ
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1177-89. PubMed ID: 8103791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
    Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of the behavioral effects of the selective dopamine D2 agonist (+)-4-propyl-9-hydroxynaphthoxazine by dopamine antagonists in monkeys.
    Rosenzweig-Lipson S; Bergman J
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1039-46. PubMed ID: 8099614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of N,N dipropyl-8-hydroxy-3-chromanamine, an oxygen isostere of the dopamine agonist N,N dipropyl-5-hydroxy-2-aminotetralin with enhanced presynaptic selectivity.
    Vermue NA; Kaptein B; Tepper PG; de Vries JB; Horn AS
    Arch Int Pharmacodyn Ther; 1988; 293():37-56. PubMed ID: 3421784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
    Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
    J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropharmacological profile of a new series of dopamine agonists: N-n-propyl-hexahydronaphthoxazines.
    Hazelhoff B; De Vries JB; Dijkstra D; Mulder TB; Timmermans PB; Wynberg H; Horn AS
    Eur J Pharmacol; 1986 May; 124(1-2):93-106. PubMed ID: 3720849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo characterization of the pharmacokinetics and pharmacological properties of [11C]-(+)-PHNO in rats using an intracerebral beta-sensitive system.
    Galineau L; Wilson AA; Garcia A; Houle S; Kapur S; Ginovart N
    Synapse; 2006 Aug; 60(2):172-83. PubMed ID: 16715499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent dopamine agonist activity of a novel ergoline, 6-ethyl-9-oxaergoline (EOE).
    Martin GE; Williams M; Clineschmidt BV; Yarbrough GG; Jones JH; Haubrich DR
    Life Sci; 1982 May; 30(21):1847-56. PubMed ID: 7201555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioural correlates to the dopamine D-1 and D-2 antagonists.
    Christensen AV; Arnt J; Hyttel J; Svendsen O
    Pol J Pharmacol Pharm; 1984; 36(2-3):249-64. PubMed ID: 6147830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.